The use of products contaminated with B. cepecia may result in local infections and possibly more serious infections in immunocompromised individuals.

Move follows RFK Jr.'s abrupt dismissal of the entire ACIP in June, alleging it was too aligned with manufacturers ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.

Significant increase seen in crude nitrous oxide poisoning rate from 2010 to 2018, but no increase seen from 2019 to 2023.

HealthDay News — Electronic cigarette (e-cigarette) flavor restriction policies are associated with reductions in e-cigarette use, according to a study published online July 30 in JAMA Network Open.

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

The sBLA for the pediatric indication is supported by data from the randomized, double-blind, placebo-controlled, phase 3 SPACE trial.

The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy.

The randomized, double-blind, CONVOKE trial evaluated the safety and efficacy of CT-155, a PDT that provides interactive psychosocial intervention techniques via a smartphone app.

Notable Drug Approvals.

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

Stronger differential effect for CPAP seen for those without excessive sleepiness, without increased blood pressure.